BPC-157

1. What is it?

BPC-157 is a synthetic peptide made of 15 amino acids, the small building blocks of proteins. Its name appears in research on protecting and repairing various tissues. Being a peptide does not establish treatment of a particular problem. An experiment showing altered cell behaviour begins an assessment; it is not equivalent to proven therapy for a person with pain, inflammation or injury. [159] [162]

2. Why do people turn to it?

People mainly seek BPC-157 for injuries, pain and faster recovery. Research covers tendons, joints and the digestive tract, among other areas, but does not establish approved indications. For a painful knee, relief differs from repairing the cause: pain may ease without cartilage rebuilding. Reports of feeling better cannot justify promises of lasting structural repair or safe return to loading the joint. [160]

3. How does it work?

An experiment published in 2011 examined pieces of rat Achilles tendon and cultured cells. BPC-157 promoted cell movement, tissue growth from the studied fragment and cell survival under difficult conditions. These processes may matter for healing. However, the study did not test whether an injured person returns to work sooner, walks better or is less likely to reinjure the tendon. Those are separate clinical questions. Cell movement is one part of healing, but tissue must also regain its proper structure and strength. Measuring cell movement alone cannot establish this. [159]

4. What do studies actually show?

A 2021 publication reviewed the records of 17 people treated for knee pain and contacted 16 by telephone. In the subgroup receiving BPC-157 alone, 11 of 12 reported improvement. The study was small, lacked an appropriate comparison group and did not use standardised measurements of joint function. A separate safety pilot, published in 2025, included only two people and very short follow-up. Those participants had previously used BPC-157, which further limits how well the findings apply to people receiving it for the first time. [160] [161]

5. What do we still not know?

A result obtained through a telephone conversation cannot separate the substance's effect from symptoms resolving naturally, rehabilitation or other changes. Without measurements taken according to the same plan, the size and duration of improvement are difficult to assess. A two-person pilot also cannot detect rare complications. Current publications therefore do not reliably establish whom BPC-157 actually helps, for which diagnosis or whether any benefit lasts over time. [160] [161]

6. What are the risks?

An absence of obvious problems in a very small pilot study does not establish safety. The FDA notes insufficient clinical data and possible immune reactions related to the peptide, its aggregates or impurities. Too little is known about the consequences of long-term use and risks in different patient groups. This uncertainty supports neither an assurance that the substance is safe nor a precise estimate of expected complications. [161] [162]

In sport governed by WADA anti-doping rules, this substance is prohibited at all times, including outside competition. The 2026 list names it explicitly. Use during training or a break between competitions is also covered by the ban. [193]

7. Is it an approved medicine?

The cited FDA assessment does not confirm an approved BPC-157 medicine. It should not be presented as an approved US treatment for injuries or intestinal disease. Consideration of a bulk substance for pharmacy compounding is separate: it does not establish a specific preparation's effectiveness or authorise a medicine in Poland. [162]

8. What is new in research?

In 2026, the FDA published a reassessment of BPC-157 covering available data on its uses and safety. It continued to identify substantial gaps in the evidence. The newer two-person pilot does not change the scale of this uncertainty. The most valuable next evidence would be an adequately sized study in patients with a specific diagnosis, measuring function, complications and longer-term outcomes. Another report of a few satisfied patients would not resolve these questions. [162] [161]

Where does this information come from?

References link to the publications and documents used. Each source includes its material type and what was reviewed; findings concern the substance, form and study population described.